- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01392248
Prediction of Pain After Breast Cancer Surgery With EEG
EEG as a Predictor for Postoperative Pain and the Development of Chronic Postsurgical Pain After Breast Cancer Surgery
- Rationale The inter-individual pain experience immediately after surgery is considerable. In addition, a number of patients develop chronic post surgery pain (CPSP). Patients undergoing surgery for breast cancer are at risk of developing both acute post surgical pain as well as CPSP. Recently, in a group of patients with chronic back pain, it was demonstrated how subjectively reported pain is associated with specific electroencephalography (EEG) parameters, namely the N2 and P3 components of the pain event-related potential (ERP). It was concluded that ERP was associated with self-reported pain in daily life up to two weeks after the measurement. This resulted in the current hypothesis that EEG may be a predictor for postoperative pain.
Study design Prospective cohort study. Within 2 weeks before surgery, 150 patients will undergo an EEG measurement with five 'vulnerability' tasks. The experiment will be repeated 6 months postoperatively.
Study population: Female patients with breast cancer who will undergo breast surgery, between the ages of 18 to 65 years.
- Main study parameters/endpoints Primary outcome is postoperative pain, measured in a pain diary 4 days postoperatively. Secondary outcomes are development of chronic post surgery pain and quality of life. The main goal is to develop a comprehensive prediction model for acute and chronic postoperative pain after breast cancer surgery, based on the EEG results of the five vulnerability experiments.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Limburg
-
Maastricht, Limburg, Países Bajos, 6200 MD
- Maastricht UMC
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Age 18 - 65 years.
- ASA 1-2.
- Sufficient comprehension of the Dutch spoken and written language.
- Elective curative breast cancer surgery, both mastectomy and breast- conserving therapy
- Stage I and II breast cancer.
- Written informed consent is obtained
Exclusion Criteria:
- Previous breast surgery, both ipsilateral and contralateral.
- Stage III-IV breast cancer.
- Chronic pain (>3months) with an average severity of at least a VAS score 4 during the last two weeks.
- Chronic pain for which invasive treatment is needed.
- Use of (weak / strong) opioids in the last week.
- A history of opioid addiction.
- Regular use of the following medications in the last year:
antiepileptics,antipsychotics and anxiolytics.
- ASA 3 or higher.
- Consumption of alcohol (>4 units) and / or drugs the evening before.
- Alcohol consumption (>= 5 units/day).
- Illiteracy, problems with self expression, language barrier.
- Serious vision and / or hearing problems, interfering the performance of the experimental tasks.
- A history of psychiatric complaints and/or epilepsy .
- A medical history of CVA or TIA.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Acute postoperative pain
Periodo de tiempo: during 4 days after surgery
|
VAS measured in a daily pain diary
|
during 4 days after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Quality of Life
Periodo de tiempo: within 2 weeks before surgery and at 3,6 and 12 months postoperatively
|
Quality of Life measured with SF-36
|
within 2 weeks before surgery and at 3,6 and 12 months postoperatively
|
Development of chronic pain
Periodo de tiempo: at 3,6 and 12 months postoperatively
|
Brief Pain Inventory
|
at 3,6 and 12 months postoperatively
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: M. A Marcus, Prof. Dr., Maastricht University Medical Center
- Investigador principal: J. van Os, Prof. Dr., Maastricht University Medical Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NL34275.068.11 / MEC 11-2-006
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos